Many vaccine-preventable diseases, such as HIV, continue to affect the world’s population and require our immediate attention. Despite more than 40 years of development, an HIV vaccine has yet to become commercially available. What have been the main challenges and opportunities with HIV and other vaccines that have emerged over that time, and how can we use those to inform future HIV vaccine development?
Join this roundtable, hosted by FHI Clinical, to discuss how we can best proceed with HIV vaccine development.
About the Facilitator
Sanchia Theron
Global Head, Medical Affairs
FHI Clinical
In her role as Global Head of Medical Affairs, Sanchia is responsible for leading a dispersed global team in the development and execution of all medical affairs activities, including medical monitoring, pharmacovigilance and medical writing. Theron previously served as associate medical director at Triclinium Clinical Development (TCD) and led the company’s business development program prior to its acquisition by FHI Clinical. In addition, during her time at TCD, she held roles including research physician and head of medical affairs where she served as a medical and pharmacovigilance expert on several large projects with local and international sponsors, ensuring all activities occurred in accordance with ICH GCP, SA GCP and global regulatory guidelines. After completing her medical degree, Theron gained valuable hands-on clinical experience working in both the public and private health sectors in South Africa. She also acted as investigator on several clinical trials before joining TCD. Although her therapeutic area experience includes a wide range of indications, the majority is focused on infectious disease and vaccine trials, especially in vulnerable populations, including children and pregnant women. Theron completed her Bachelor of Medicine and Bachelor of Surgery (MBChB) from the University of Pretoria.
